The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists | 40 min

(0 review)
1253
students
0
Free

The role of the Pathologist is crucial in the emerging field of neoadjuvant therapy in melanoma. Understanding that their role is fundamental to patient...

Free

Diagnosis and management of uveal melanoma | 44 min

(0 review)
1264
students
0
Free

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic...

Free

Refining pathological response assessment in neoadjuvant therapy for melanoma | 40 min

(1 review)
1300
students
1
Free

In this presentation, Pathologist Prof Richard Scolyer AO discusses how neoadjuvant therapy is transforming melanoma patient care. He also answers key questions around neoadjuvant-treated...

Free

The future of melanoma and surgical oncology | 52 min

(0 review)
1471
students
0
Free

This presentation was recorded at A/Prof Alexander van Akkooi’s inaugural Australian lecture where he discusses his vision and aims for the future of melanoma...

Free

Critical questions for a melanoma pathologist | 36 min

(0 review)
1548
students
0
Free

The role of pathologist in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the...

Free

Toxicity management in melanoma | 45 min

(0 review)
1677
students
0
Free

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of...

Free

Update on the adjuvant treatment of melanoma in 2021 | 13 min

(0 review)
1808
students
0
Free

In this presentation, A/Prof Andrew Haydon reviews the efficacy data from 6 large-scale Phase III studies that are looking at the use of modern...

Free

Staging melanoma and bulky palpable Stage III melanoma – is surgery necessary? | 10 min

(0 review)
1808
students
0
Free

In this presentation, A/Prof Sydney Ch’ng discovers the current recommendations for sentinel node biopsy and the implications of high-risk Stage II melanoma trial findings....

Free

Management of in-transit melanoma in the time of active systemic therapy | 11 min

(0 review)
1808
students
0
Free

With up to 14% of patients developing in-transit disease and biologically diverse pathobiological behaviour is observed, in-transit disease is a significant clinical burden. In...

Free